



Clinical trial results:

A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness

Summary

EudraCT number	2011-006062-40
Trial protocol	DE SE
Global end of trial date	12 December 2013

Results information

Result version number	v1 (current)
This version publication date	09 April 2018
First version publication date	09 April 2018

Trial information

Trial identification

Sponsor protocol code	I1Q-MC-JDDJ
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01604408
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 14499

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-285-4559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 December 2013
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 December 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study, in older patients who have fallen recently and have muscle weakness, is to test the hypothesis that LY2495655 will increase appendicular lean body mass(aLBM) versus placebo 24 weeks after starting treatment.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 May 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	3 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Sweden: 18
Country: Number of subjects enrolled	France: 25
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	United States: 73
Country: Number of subjects enrolled	Argentina: 36
Country: Number of subjects enrolled	Australia: 36
Worldwide total number of subjects	201
EEA total number of subjects	56

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	144
85 years and over	57

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

No text entered.

Period 1

Period 1 title	Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Experimental: LY2495655
------------------	-------------------------

Arm description:

Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.

Arm type	Experimental
Investigational medicinal product name	LY2495655
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.

Arm title	Placebo
------------------	---------

Arm description:

Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.

Arm type	Placebo Comparator
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.

Number of subjects in period 1	Experimental: LY2495655	Placebo
Started	102	99
Received at Least 1 Dose of Study Drug	102	99
Completed	86	87
Not completed	16	12
Consent withdrawn by subject	6	3
Adverse event, non-fatal	6	5
Protocol violation	2	2
Death	1	-
Sponsor decision	1	1
Lost to follow-up	-	1

Period 2

Period 2 title	Observation
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Experimental: LY2495655

Arm description:

Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.

Arm type	Experimental
Investigational medicinal product name	LY2495655
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.

Arm title	Placebo
------------------	---------

Arm description:

Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.

Arm type	Placebo Comparator
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.

Number of subjects in period 2	Experimental: LY2495655	Placebo
Started	86	87
Completed	85	84
Not completed	1	3
Consent withdrawn by subject	-	2
Adverse event, non-fatal	1	1

Baseline characteristics

Reporting groups

Reporting group title	Experimental: LY2495655
Reporting group description:	
Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.	
Reporting group title	Placebo
Reporting group description:	
Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.	

Reporting group values	Experimental: LY2495655	Placebo	Total
Number of subjects	102	99	201
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	81.84	82.57	
standard deviation	± 4.73	± 5.2	-
Gender categorical			
Units: Subjects			
Female	75	65	140
Male	27	34	61
Ethnicity			
Units: Subjects			
Hispanic or Latino	17	19	36
Not Hispanic or Latino	48	45	93
Unknown or Not Reported	37	35	72
Race			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	101	98	199
More than one race	1	0	1
Unknown or Not Reported	0	0	0
Region of Enrollment			
Units: Subjects			
France	13	12	25
United States	37	36	73
Argentina	17	19	36
Australia	19	17	36
Germany	6	7	13
Sweden	10	8	18

End points

End points reporting groups

Reporting group title	Experimental: LY2495655
Reporting group description: Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.	
Reporting group title	Placebo
Reporting group description: Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.	
Reporting group title	Experimental: LY2495655
Reporting group description: Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.	
Reporting group title	Placebo
Reporting group description: Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.	

Primary: Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM)

End point title	Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM)
End point description: Change from baseline to 24-week endpoint in aLBM, as measured by dual energy x-ray absorptiometry (DEXA), is presented. Least squares (LS) means were calculated using a mixed model repeated measures (MMRM) with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline aLBM as covariate.	
End point type	Primary
End point timeframe: Baseline to 24 weeks	

End point values	Experimental: LY2495655	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	77 ^[1]	82 ^[2]		
Units: Kilograms				
least squares mean (standard error)	0.303 (± 0.085)	-0.123 (± 0.083)		

Notes:

[1] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable aLBM data.

[2] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable aLBM data.

Statistical analyses

Statistical analysis title	Change From Baseline to 24 Week Endpoint in aLBM
Comparison groups	Experimental: LY2495655 v Placebo

Number of subjects included in analysis	159
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	LS Mean Difference
Point estimate	0.426
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.192
upper limit	0.66

Secondary: Change From Baseline in Stair Climbing (StC) Time

End point title	Change From Baseline in Stair Climbing (StC) Time
End point description:	
Change from baseline to the 24-week endpoint in StC time is presented. StC time was assessed by measuring the fastest time achieved to climb 4 steps on a 4-step staircase (the test was performed 2 times). LS means were calculated using a MMRM with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline StC score as covariate.	
End point type	Secondary
End point timeframe:	
Baseline to 24 weeks	

End point values	Experimental: LY2495655	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	80 ^[3]	84 ^[4]		
Units: Seconds				
least squares mean (standard deviation)	-0.276 (± 0.182)	0.184 (± 0.178)		

Notes:

[3] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable StC time data.

[4] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable StC time data.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Repeated Chair Stands (RCS) Time

End point title	Change From Baseline in Repeated Chair Stands (RCS) Time
End point description:	
Change from baseline to 24-week endpoint in RCS time is presented. In the RCS test, participants were asked to rise from a chair 5 times as fast as possible with their arms folded on their chest. Performance was measured in seconds, as the time from the initial seated position to the final standing position. LS means were calculated using an MMRM with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline RCS time as covariate.	
End point type	Secondary

End point timeframe:

Baseline to 24 weeks

End point values	Experimental: LY2495655	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53 ^[5]	64 ^[6]		
Units: Seconds				
least squares mean (standard error)	-1.888 (± 0.588)	0.826 (± 0.551)		

Notes:

[5] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable RCS time data.

[6] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable RCS time data.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Usual Gait Speed (uGS) at 4 Meters

End point title	Change From Baseline in Usual Gait Speed (uGS) at 4 Meters
-----------------	--

End point description:

Change from baseline to the 24-week endpoint in uGS is presented. Two attempts to walk a 4-meter distance were made. LS means were calculated using a MMRM with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline uGS as covariate.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to 24 weeks

End point values	Experimental: LY2495655	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	80 ^[7]	85 ^[8]		
Units: meters per second (m/s)				
least squares mean (standard error)	0.03 (± 0.017)	0.013 (± 0.017)		

Notes:

[7] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable uGS data.

[8] - All participants who received at least 1 dose of LY2495655 or placebo with evaluable uGS data.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

I1Q-MC-JDDJ

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

Reporting groups

Reporting group title	LY2495655
-----------------------	-----------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	LY2495655	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 102 (26.47%)	18 / 99 (18.18%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma pancreas			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lung neoplasm malignant			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
non-hodgkin's lymphoma			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pancreatic carcinoma			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
hypertensive crisis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
rotator cuff repair			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
device dislocation			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
injection site haemorrhage			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pyrexia			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
acute respiratory failure			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypoxia			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary arterial hypertension			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
respiratory alkalosis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
international normalised ratio increased			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
liver function test abnormal			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
ankle fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
avulsion fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
clavicle fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
fall			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	2 / 102 (1.96%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
femur fracture			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	2 / 102 (1.96%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
fibula fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
head injury			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hip fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
radius fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
rib fracture			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

scapula fracture alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
tendon rupture alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
thoracic vertebral fracture alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
tibia fracture alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
upper limb fracture alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
angina pectoris alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
atrioventricular block first degree alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
bradycardia			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
sinoatrial block			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
syncope			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
thalamus haemorrhage			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
transient ischaemic attack			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	1 / 102 (0.98%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
normochromic normocytic anaemia alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders deafness unilateral alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders colitis ischaemic alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
small intestinal obstruction alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
tooth socket haemorrhage alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
urinary retention			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
back pain			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
groin pain			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
osteoarthritis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pain in jaw			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
diverticulitis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
epiglottitis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
escherichia urinary tract infection			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
herpes zoster oticus			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
localised infection			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
staphylococcal sepsis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	0 / 102 (0.00%)	1 / 99 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
diabetes mellitus inadequate control			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyponatraemia			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
lactic acidosis			
alternative dictionary used: MedDRA 16.1			

subjects affected / exposed	1 / 102 (0.98%)	0 / 99 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	LY2495655	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	90 / 102 (88.24%)	77 / 99 (77.78%)	
Injury, poisoning and procedural complications			
contusion			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	7 / 102 (6.86%)	9 / 99 (9.09%)	
occurrences (all)	9	11	
Nervous system disorders			
headache			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	7 / 102 (6.86%)	4 / 99 (4.04%)	
occurrences (all)	8	4	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	4 / 102 (3.92%)	5 / 99 (5.05%)	
occurrences (all)	4	5	
fatigue			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	12 / 102 (11.76%)	3 / 99 (3.03%)	
occurrences (all)	14	3	
injection site bruising			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	6 / 102 (5.88%)	0 / 99 (0.00%)	
occurrences (all)	8	0	
injection site pain			
alternative dictionary used: MedDRA 16.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pain</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>20 / 102 (19.61%)</p> <p>69</p> <p>5 / 102 (4.90%)</p> <p>5</p>	<p>5 / 99 (5.05%)</p> <p>7</p> <p>6 / 99 (6.06%)</p> <p>8</p>	
<p>Gastrointestinal disorders</p> <p>constipation</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 102 (6.86%)</p> <p>8</p> <p>6 / 102 (5.88%)</p> <p>8</p>	<p>3 / 99 (3.03%)</p> <p>3</p> <p>7 / 99 (7.07%)</p> <p>8</p>	
<p>Respiratory, thoracic and mediastinal disorders</p> <p>cough</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 102 (6.86%)</p> <p>7</p>	<p>4 / 99 (4.04%)</p> <p>5</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>muscle spasms</p> <p>alternative dictionary used: MedDRA 16.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pain in extremity</p> <p>alternative dictionary used:</p>	<p>19 / 102 (18.63%)</p> <p>20</p> <p>11 / 102 (10.78%)</p> <p>11</p> <p>7 / 102 (6.86%)</p> <p>9</p>	<p>13 / 99 (13.13%)</p> <p>13</p> <p>4 / 99 (4.04%)</p> <p>4</p> <p>3 / 99 (3.03%)</p> <p>3</p>	

MedDRA 16.1			
subjects affected / exposed	7 / 102 (6.86%)	10 / 99 (10.10%)	
occurrences (all)	9	10	
Infections and infestations			
nasopharyngitis			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	7 / 102 (6.86%)	8 / 99 (8.08%)	
occurrences (all)	10	8	
upper respiratory tract infection			
alternative dictionary used: MedDRA 16.1			
subjects affected / exposed	3 / 102 (2.94%)	6 / 99 (6.06%)	
occurrences (all)	3	6	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 April 2012	Creation of an assessment committee independent from the study team (for safety monitoring.
08 June 2012	Planned additional interim analysis after 70 patients have been enrolled.
04 September 2012	Addition of some screening blood tests and related exclusion criteria (hypothyroidism, male hypogonadism, hyponatremia, polymyalgia rheumatica.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported